January 12, 2017

Mosquito Wars

for V-Bio Ventures

Mosquitoes are carriers of a range of crippling diseases, posing an enormous global health burden. Because current methods based on insecticides are inadequate, new tools are urgently needed. Widely different companies are tackling the problem of mosquito control from very different angles; who will be successful in getting a grip on these tiny flying terrors? A view by V-Bio Ventures.

December 13, 2016

Confo Therapeutics: Drugging the Undruggable

for V-Bio Ventures

December 6, 2016

Music or neuroscience? Balthazar’s violinist chose music (at least for now)

for BioVox

For Patricia Vanneste, violinist with the popular rock group Balthazar, it wasn’t a choice she made lightly. Patricia has played the violin since she was five. [...]

November 16, 2016

Multiplicom: a strong focus on DNA analysis

for BioVox

November 15, 2016

Second and third lives for known cancer drugs

for BioVox

November 14, 2016

The choroid plexus: where inflammation meets neurology

for BioVox

We write about change — about impact and consequences, about discoveries and the people behind them. This time, we introduce you to Roosmarijn Vandenbroucke, a discovery scientist at IRC-VIB and a professor at Ghent University. She gives us an eagle’s-eye view of her group’s latest research, which has the potential to impact the management of patients with neurodegenerative and neuroinflammatory diseases.

October 14, 2016

ADHD, a disorder cured by play

for BioVox

In 2013, a new BioWin project, NeuroAtt, was launched to arrive at a reliable diagnosis for ADHD (Attention Deficit Hyperactivity Disorder) and to find the least [...]

October 14, 2016

Arming cells with a cancer vaccine

for BioVox

October 14, 2016

Jeroen Pollet in Texas – Belgian scientist living abroad

for BioVox

Houston (Texas, USA) has been home to Jeroen Pollet since August 2011. He arrived as a Fulbright scholar; now he is an assistant professor at Baylor College of Medicine (BCM), and also the director of the Formulation Development Unit at the Sabin Vaccine Institute & Texas Children`s Hospital Center for Vaccine Development. In these roles, he develops new vaccines against neglected tropical diseases and studies the interactions of vaccine antigens with immunostimulatory agents in relation to immune responses and vaccine efficacy.

August 29, 2016

Huge steps forward in VIB skin cancer research

for BioVox

July 14, 2016

CAR-T: The T-cell training program to fight cancer

for BioVox

June 21, 2016

Colistin: breaking the last line of antibiotic defense

for BioVox

A first case of colistin resistance has been described in the US. This is troubling news, since colistin is used as a last-resort drug in combating infections with highly antibiotic-resistant bacteria. The intensive use of colistin in the pork industry, mainly in China, is suspected to have caused the development of this resistance. Now, the trait is spreading rapidly; does this herald the beginning of a post-antibiotics era?